Novobiotronics Delivers Major Blow to Cancer and MRSA

Novobiotronics (Novobiotronics.com), a world leader in research on the biological effects of Oscillating Pulsed Electric Fields (OPEF) as a future nontoxic medical treatment, has delivered a major blow against cancer and antibiotic resistant bacteria using a pulsed electronic signal that has destroyed cancer cells and disabled antibiotic resistance in deadly MRSA and pseudomonas bacteria.

News provided by

Novobiotronics Inc.

Oct 22, 2013, 08:30 ET

SARATOGA SPRINGS, N.Y., Oct. 22, 2013 /PRNewswire/ -- Novobiotronics was the first company to document the ability of oscillating pulsed electric fields (OPEF) to destroy 30%-60% of cancerous leukemia cells. In laboratory experiments, OPEF also demonstrated an ability to slow cancer growth by up to 60%. In new breakthrough research, OPEF has also shown an ability to disable antibiotic resistance in the deadly bacteria MRSA, rendering it vulnerable to commonly available antibiotics as well as slowing its growth.

Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment ((C)2011 Novobiotronics Inc.). (PRNewsFoto/Novobiotronics Inc.) (PRNewsFoto/NOVOBIOTRONICS INC.)

The lower of two pancreatic cancer cells shattered by nontoxic OPEF treatment. (PRNewsFoto/Novobiotronics Inc.) (PRNewsFoto/NOVOBIOTRONICS INC.)

(Photo: http://photos.prnewswire.com/prnh/20131022/PH01064-a )
(Photo: http://photos.prnewswire.com/prnh/20131022/PH01064-b )

Novobiotronics Inc., a nonprofit educational and scientific research company headquartered in upstate New York, has announced a major breakthrough in the fight against cancer and dangerous antibiotic resistant strains of bacteria including the 'superbug' fatal menace of MRSA, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa, or PS.

Anthony Holland, President of Novobiotronics Inc., was proud to announce the results of recent laboratory experiments by Novobiotronics, in collaboration with the State University of New York, that indicate that their new electronic treatment of antibiotic resistant MRSA and PS has both a 'bacteriostatic' effect (the growth rate of the deadly strain was tremendously slowed) as well as a bactericidal effect (it kills the bacteria) when used in conjunction with tiny amounts of standard antibiotics to which the deadly organisms are otherwise normally resistant.

According to the US Center for Disease Control and Prevention, nearly 90,000 people die each year in the United States from antibiotic-resistant bacterial infections, more deaths than breast cancer and prostrate cancer combined. MRSA is now "endemic, and even epidemic in many US hospitals." From 1999 through 2005, MRSA-related hospitalizations more than doubled from 127,036 to 278,203. It appears that more people in the U.S. now die from the mostly hospital-acquired staph infection MRSA than from AIDS. In addition to deadly MRSA outbreaks in communities across the country, of the two million hospital acquired infections each year, 10% are caused by the antibiotic resistant Pseudomonas (PS), which can often lead to life threatening intensive care unit (ICU) pneumonia and other serious medical conditions.

The current mainstream medical treatment of antibiotic resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Doctors even induce some patients into a coma in order to lessen the severity of the drug side effects.

Novobiotronics' new discovery involves the use of a 'plasma antenna', a special type of a helium gas filled fluorescent light, which is used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These oscillating pulsed electric fields (OPEF) can kill cancer cells, slow the growth rate of the cancer cells and bacteria tremendously, and actually nullify the bacteria's ability to resist antibiotics. When used in conjunction with tiny amounts of a standard antibiotic, OPEF has demonstrated an ability to kill the deadly MRSA and PS bacteria. Novobiotronics' collaborators from the State University of New York presented their joint findings at a recent meeting of the American Society for Microbiology in Denver, Colorado.

For More Information:
http://www.indiegogo.com/projects/stop-the-suffering-of-children-with-cancer/x/1373370

Contact Information:
Anthony Holland, President, Novobiotronics Inc.,
Email, PO Box 1210, Saratoga Springs, NY 12866